🇺🇸 FDA
Pipeline program

18F-DPA-714

Phase 3 small_molecule active

Quick answer

18F-DPA-714 for Multiple sclerosis is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).

Program details

Company
Pari Pharma GmbH
Indication
Multiple sclerosis
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials